Anticancer activity of polyoxomolybdate - 21/03/08

Doi : 10.1016/j.biopha.2006.06.018

H. Yanagie ^a,^⁎ , A. Ogata ^b, S. Mitsui ^b, T. Hisa ^a, T. Yamase ^b, M. Eriguchi ^a
^a Department of Intellectual Property, Project of Cancer Metastasis Inhibition, Research Center for Advanced Science and Technology, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo 153-8904, Japan
^b Chemical Research Laboratory, Tokyo Institute of Technology, R1-21, 4259 Nagatsuta, Midori-ku, Yokohama 226-8503, and “Creation of bio-devices and bio-systems with chemical and biological molecules for medical use”, CREST, Japan Science and Technology Agency (JST), Japan

Corresponding author. Tel.: +81 3 5452 5436; fax: +81 3 5452 5434.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	4
Iconographies	0
Vidéos	0
Autres	0

Abstract

Anticancer polyoxomolybdates have been investigated for medical application of polyoxometalates as discrete cluster anions of metal oxides. [NH₃Prⁱ]₆[Mo₇O₂₄]·3H₂O (PM-8) has been recognized as one of significant antitumoral polyoxomolybdates. PM-8 had shown the growth suppression against several tumors, for examples, Co-4, human colon cancer, MX-1, human breast cancer, and OAT, human lung cancer. PM-8 showed the tumor growth suppression for MKN-45 human gastric cancer in tumor bearing mice. PM-8 inhibited the cell growth of AsPC-1 which depended on the dose with showing DNA ladder formation and DNA fragmentation, and positive Hoechst staining indicating apoptosis. The ratio of apoptotic cells on flow cytometry analysis were 35%, and 57% with treatment of PM-8 after 48, and 72 h, respectively. One of the anti-tumor activity of PM-8 result from the activation of apoptotic pathway. It is thought that polyoxomolybdates will be applied as a novel anti-tumor agent especially against cancers which are difficult to be treated clinically.

Le texte complet de cet article est disponible en PDF.

Keywords : Polyoxomolybdate, Cancer growth inhibition, Apoptosis, Redox reaction

Plan

Background

Cancer cell cytotoxicity and tumor growth suppression of polyoxomolybdate

Anticancer mechanisms of polyoxomolybdate

Export

Vol 60 - N° 7

P. 349-352 - août 2006 Retour au numéro

Article précédent

The role of ketamine in pain management
E. Visser, S.A. Schug

| Article suivant

Antitumor activity of polyoxomolybdate, [NH₃Prⁱ]₆[Mo₇O₂₄]·3H₂O, against, human gastric cancer model
S. Mitsui, A. Ogata, H. Yanagie, H. Kasano, T. Hisa, T. Yamase, M. Eriguchi

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Anticancer activity of polyoxomolybdate - 21/03/08

Abstract

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL